BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foy KC, Miller MJ, Moldovan N, Carson WE 3rd, Kaumaya PT. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology 2012;1:1048-60. [PMID: 23170253 DOI: 10.4161/onci.20708] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Pan L, Weng R, Zhang J, Wang J, Tang Y, Deng N. Immune Response of the VEGF/bFGF Complex Peptide Vaccine and Function of Immune Antibodies in Inhibiting Migration of HUVEC Cells and Proliferation of Cancer Cells. Int J Pept Res Ther 2014;20:565-74. [DOI: 10.1007/s10989-014-9414-z] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012;2012:967347. [PMID: 23316341 DOI: 10.1155/2012/967347] [Cited by in Crossref: 198] [Cited by in F6Publishing: 191] [Article Influence: 19.8] [Reference Citation Analysis]
3 Raddum AM, Hollås H, Shumilin IA, Henklein P, Kretsinger R, Fossen T, Vedeler A. The native structure of annexin A2 peptides in hydrophilic environment determines their anti-angiogenic effects. Biochem Pharmacol 2015;95:1-15. [PMID: 25772737 DOI: 10.1016/j.bcp.2015.02.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
4 Zhang L, Deng Y, Zhang Y, Liu C, Zhang S, Zhu W, Tang Y, Deng N. The Design, Characterizations, and Tumor Angiogenesis Inhibition of a Multi-Epitope Peptibody With bFGF/VEGFA. Front Oncol 2020;10:1190. [PMID: 32766160 DOI: 10.3389/fonc.2020.01190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Kaumaya PT. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncol 2020;16:1767-91. [PMID: 32564612 DOI: 10.2217/fon-2020-0224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang L, Zhou R, Zhao Y, Dong S, Zhang J, Luo Y, Huang N, Shi M, Bin J, Liao Y, Liao W. MACC-1 Promotes Endothelium-Dependent Angiogenesis in Gastric Cancer by Activating TWIST1/VEGF-A Signal Pathway. PLoS One 2016;11:e0157137. [PMID: 27280289 DOI: 10.1371/journal.pone.0157137] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
7 Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15:325-340. [PMID: 29508855 DOI: 10.1038/nrclinonc.2018.29] [Cited by in Crossref: 440] [Cited by in F6Publishing: 443] [Article Influence: 110.0] [Reference Citation Analysis]
8 Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
9 Zheng T, Wang A, Hu D, Wang Y. Tumor-targeting templated silica nanoparticles as a dual-drug delivery system for anti-angiogenic ovarian cancer therapy. Exp Ther Med 2017;14:2162-70. [PMID: 28962137 DOI: 10.3892/etm.2017.4777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
10 Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology 2014;3:e956012. [PMID: 25941588 DOI: 10.4161/21624011.2014.956012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
11 Kaumaya PT. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother 2015;11:1368-86. [PMID: 25874884 DOI: 10.1080/21645515.2015.1026495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
12 Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013;2:e23803. [PMID: 23734328 DOI: 10.4161/onci.23803] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 8.5] [Reference Citation Analysis]
13 Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clin Cancer Res 2019;25:3495-507. [PMID: 30804020 DOI: 10.1158/1078-0432.CCR-18-3997] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
14 Zhang Q, Lao X, Huang J, Zhu Z, Pang L, Tang Y, Song Q, Huang J, Deng J, Deng N, Yang Q, Sengupta AM, Xiong L. Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide. Biotechnol Prog 2015;31:194-203. [PMID: 25271020 DOI: 10.1002/btpr.1997] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
15 Kaumaya PT. Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics. Immunotherapy 2013;5:1159-63. [PMID: 24188668 DOI: 10.2217/imt.13.128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
16 Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson WE 3rd, Kaumaya PT. Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. Oncoimmunology 2012;1:1004-16. [PMID: 23170249 DOI: 10.4161/onci.21057] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
17 Zhang L, He D, Huang J, Deng Y, Weng R, Pan L, Deng N. The Immunogenicity and Immunoprotection of VBP3 Multi-epitope Vaccine Targeting Angiogenesis and Tumor Inhibition in Lung Cancer-Bearing Mice. Int J Pept Res Ther 2019;25:215-25. [DOI: 10.1007/s10989-017-9667-4] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Mohit E, Hashemi A, Allahyari M. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Review of Clinical Immunology 2014;10:927-61. [DOI: 10.1586/1744666x.2014.916211] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
19 Zhang S, Wang H, Ding X, Xiao Y, Shao Z, You C, Gu Y, Jiang Y. Bidirectional Crosstalk between Therapeutic Cancer Vaccines and the Tumor Microenvironment: Beyond Tumor Antigens. Fundamental Research 2022. [DOI: 10.1016/j.fmre.2022.03.009] [Reference Citation Analysis]
20 Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel) 2015;3:519-43. [PMID: 26350593 DOI: 10.3390/vaccines3030519] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
21 Foy KC, Miller MJ, Overholser J, Donnelly SM, Nahta R, Kaumaya PT. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides. Oncoimmunology 2014;3:e956005. [PMID: 25941587 DOI: 10.4161/21624011.2014.956005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
22 Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L. Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol 2015;2:e974463. [PMID: 27308423 DOI: 10.4161/23723556.2014.974463] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
23 Kaumaya PT, Foy KC. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 2012;8:961-987. [PMID: 22894670 DOI: 10.2217/fon.12.95] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
24 Rahat MA. Targeting Angiogenesis With Peptide Vaccines. Front Immunol 2019;10:1924. [PMID: 31440262 DOI: 10.3389/fimmu.2019.01924] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]